Major Career Roles:
- Served as Chair and CEO at Eli Lilly & Co. now Chair Emeritus
- Board Member and Chair of the Compensation Committee of IBM and of Mc-Graw-Hill (now S&P Global)
- Chair of Pearson plc
Other Career Highlights:
- Council Member of the President’s Homeland Security Advisory Council
- Council Member of the President’s Export Council
- Member of the Advisory Committee for Trade Policy and Negotiations.
- Member of the Boards of ITT Inc.
- Partner at Capital Royalty LP, now the CRG LP
- Advisory Board Member at the global investment bank Moelis & Co.
- Advisory Board Member at Almirall SA
Sidney Taurel has a vast wealth of international senior leadership experience with 20 years as Chair and CEO of FTSE 100, S&P 100, S&P 500, and private companies with multi-industry knowledge in education, finance, pharmaceuticals, publishing, and technology.
Sidney was previously Chair of Pearson plc, the world’s largest publishing and education company and a Board Member of HIG Acquisition Corporation. He is also Chair Emeritus at Eli Lilly & Co, and a member of the ATP (Association of Tennis Professionals) Audit and Finance Committee.
Sidney spent most of his career with the global pharmaceutical firm Eli Lilly & Co., a SPAC listed on the NYSE, where he served as CEO and Chair up to 2008, becoming Chair Emeritus in 2009.
During his time at Eli Lilly, Sidney also held three US Presidential appointments, serving firstly as a Council Member of the President’s Homeland Security Advisory Council, then on the President’s Export Council, and in 2007 becoming a member of the Advisory Committee for Trade Policy and Negotiations.
Sidney was also a member of the Boards of ITT Inc. where he chaired the Audit Committee and IBM Corp. where he chaired the Compensation Committee and of the McGraw-Hill companies (now S&P Global), where he chaired the Remuneration Committee.
He was also a Partner at Capital Royalty LP, now the CRG LP, and an Advisory Board Member at the global investment bank Moelis & Co., the Japanese company Takeda Pharmaceutical Co. Ltd and the Spanish pharmaceutical company Almirall SA.